Exagen Affirms FY2026 Sales Guidance of $70.000M-$73.000M vs $71.267M Est

Benzinga Newsdesk www.benzinga.com Negative 70.8%

Neg 70.8% Neu 0% Pos 0%

Exagen (NASDAQ:XGN) affirms FY2026 sales outlook from $70.000 million-$73.000 million to $70.000 million-$73.000 million vs $71.267 million estimate.